Erratum

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Sanna Rosengren,^{1,5} Samuel S. Dychter,¹ Marie A. Printz,¹ Lei Huang,¹ Richard I. Schiff,² Hans-Peter Schwarz,³ John K. McVey,⁴ Fred H. Drake,¹ Dan C. Maneval,¹ Don A. Kennard,¹ Gregory I. Frost,¹ Barry J. Sugarman,¹ and Douglas B. Muchmore¹

Published online 4 September 2015

Erratum to: AAPS J
DOI 10.1208/s12248-015-9782-0

Errors by the authors were inadvertently published in Table I and the supplemental material. The correct Table I is below and the corrected supplemental material can be found by accessing the original article.

The online version of the original article can be found at <http://dx.doi.org/10.1208/s12248-015-9782-0>.

¹ Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, California 92121, USA.

² Baxter Bioscience, Deerfield, Illinois, USA.

³ Baxter Bioscience, Vienna, Austria.

⁴ Baxter Healthcare Corporation, Deerfield, Illinois, USA.

⁵ To whom correspondence should be addressed. (e-mail: srosengren@halozyme.com)

Table 1. Overview Over All Included Clinical Trials

Trial	ClinTrials.gov reference	Population	Co-administered therapeutic	rHuPH20 dose	rHuPH20 dosing frequency	Duration of rHuPH20 treatments	Duration of available immunogenicity data
117-203 117-205	NCT00883558 NCT01194245	Type I diabetes mellitus Type I diabetes mellitus	Prandial insulin Prandial insulin analog	variable 77 (12-268) U daily ^a	3 times daily 3 times daily	3 months 12 weeks	Up to 6 months Up to 6 months
117-206	NCT01194258	Type II diabetes mellitus	Prandial insulin analog	245 (22-1489) U daily	3 times daily	12 weeks	Up to 6 months
117-403	NCT01848990	Type I diabetes mellitus	Continuous SC insulin infusion	150 U per treatment event	Every 2-3 days	Up to 21 months	183 (30-183) days
HannaH	BO22227, NCT00950300	HER2-positive breast cancer	Trastuzumab	10,000 U per treatment event	Every 3 weeks	18 cycles of 3 weeks each	724 (85-944) days
SparkThera SABRINA	BP22333, NCT00930514 BO22334, NCT01200758	Follicular lymphoma Follicular lymphoma	Rituximab Rituximab	23,400 U per treatment event 23,400 U per treatment event	Every 2-3 months Every 8 weeks	Up to 2 years (Stage 2) Up to 2 years	85 (17-646) days 315 (116-842) days
SAWYER	BO25341, NCT01292603	Chronic lymphocytic leukemia	Rituximab	26,740 U per treatment event	Once per 5 of 6 cycles (stage 2)	Up to 2 years	133 (28-399) days
160603/902	160603; NCT00814320 160902; NCT01175213	Primary immunodeficiency	Human IgG	2800 (800-6400) U per treatment event	Every 3-4 weeks	Up to 3 years	1414 (337-1599) days
Normals	n/a	Healthy plasma donors	n/a	n/a	n/a	n/a	Single sample

^a When applicable, data are presented as median (min-max)